JOT108
- Positive resveratrol outcomes in Alzheimer’s Disease (AD) has fueled interest due to failures in multiple anti-amyloid trials.
- In a 119 patient dose escalation Phase 2 AD study, resveratrol demonstrated stabilization of key biomarkers, including amyloid levels in CSF and plasma.
- Compared to the placebo-treated group, at 52 weeks, resveratrol markedly reduced CSF MMP9 and increased macrophage-derived chemokine (MDC), interleukin (IL)-4, and fibroblast growth factor (FGF)-2.
- Compared to baseline, resveratrol increased plasma MMP10 and decreased IL-12P40, IL12P70, and RANTES. In this subset analysis, resveratrol treatment attenuated declines in mini-mental status examination (MMSE) scores, change in ADL (ADCS-ADL) scores, and CSF Aβ42 levels during the 52-week trial, but did not alter tau levels.
- Conclusions: Collectively, these data suggest that resveratrol decreases CSF MMP9, modulates neuro-inflammation, and induces adaptive immunity. SIRT1 activation may be a viable target for treatment or prevention of neurodegenerative disorders. Trial registration: ClinicalTrials.govNCT01504854
- Based on other positive resveratrol neurological studies with a pharmacokinetic component (4), the highest dose administered in AD did not generate the plasma levels of resveratrol that the investigators and JOT believes is needed for full therapeutic effect of resveratrol in treatment of AD, which can be achieved through JOTROL administration.
2. Moussa C et al, Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer’s disease. J Neuroinflammation. 2017 Jan 3;14(1):1. doi: 10.1186/s12974-016-0779-0. PMID: 28086917. (Selected as Editor’s Choice: Martin I: Resveratrol for Alzheimer’s disease. Science Translational Medicine. 2017 Feb;9:375).
3. SawdaC et al, Ann NY AcadSci. 2017 Sep;1403(1):142-149. doi: 10.1111/nyas.13431. Epub2017 Aug 16. PMID 28815614.
4. YiuEM et al, J Neurol. 2015 May;262(5):1344-53. doi: 10.1007/s00415-015-7719-2. Epub2015 Apr 7.